Neurocrine Biosciences, Inc. announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1140675 in healthy adult participants. NBI-1140675 is an oral, selective second-generation small molecule inhibitor of the vesicular monoamine transporter 2 (VMAT2).
This compound is in development for the potential treatment of certain neurological and neuropsychiatric conditions. NBI-1140675 is an internally discovered, highly potent, selective VMAT2 inhibitor with the potential to provide differentiated benefits.
NBI-1140675 joins NBI-1065890 as another second-generation VMAT2 inhibitor undergoing evaluation in Phase 1 clinical studies. This initiative extends Neurocrine's expertise in VMAT2 inhibition, building on the success of valbenazine for tardive dyskinesia and chorea in Huntington's disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.